-27.7%
PDD vs GSK
+65.8%
-93.5%
-53.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.9% | +0.5% | +1.3% | +1.8% |
| 7D | -4.9% | +1.1% | -6.0% | -5.1% |
| 30D | -3.0% | +6.3% | -9.4% | -4.1% |
| 3M | -6.2% | +1.8% | -8.0% | -6.5% |
| 6M | -20.7% | +1.7% | -22.4% | -21.2% |
| YTD | -30.4% | +6.5% | -36.9% | -31.4% |
| 1Y | -41.3% | +9.5% | -50.8% | -42.4% |
| 3Y | -27.7% | +65.3% | -93.0% | -34.9% |
| All | -27.7% | +65.8% | -93.5% | -34.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling